Safety of hormonal contraception among women with liver disease: an updated systematic review
Authors:
- 7 July 2025
- journal article
- review article
- Published by Elsevier in Contraception
- Vol. 159, 111012
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health
This publication has 42 references indexed in Scilit:
- Body weight changes and duration of estrogen exposure modulate the evolution of hepatocellular adenomas after contraception discontinuationHepatology, 2022
- Reproductive Health and Liver Disease: Practice Guidance by the American Association for the Study of Liver DiseasesHepatology, 2021
- The effects of hormonal contraceptive use among women with viral hepatitis or cirrhosis of the liver: a systematic reviewContraception, 2009
- Hormonal contraceptive use among women with liver tumors: a systematic reviewContraception, 2009
- Pharmacokinetics and dosage adjustment in patients with hepatic dysfunctionEuropean Journal of Clinical Pharmacology, 2008
- Progression of Liver Fibrosis in Women Infected With Hepatitis C: Long–Term Benefit of Estrogen ExposureHepatology, 2004
- Safety of hormonal steroid contraceptive use for hepatitis B virus carrier womenPharmacoepidemiology and Drug Safety, 2000
- Effects of progestogens on haemostasisMaturitas, 1996
- Effects of oral contraception on liver function tests and serum proteins in women with past viral hepatitisContraception, 1982
- Oral Contraceptives in Acute Viral HepatitisJAMA, 1975